Scedosporium prolificans: an emerging pathogen in France? (scientific article published on 12 December 2008)

Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum

Q34109768

Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999.

Q34243482

Disseminated phaeohyphomycosis: review of an emerging mycosis

Q34498615

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

Q34574325

Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients

Q35587146

Scedosporium species infections and treatments

Q35622016

Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used?

Q36521179

Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients

Q36531721

Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient

Q36788595

Changing epidemiology of rare mould infections: implications for therapy

Q36920608

Molecular typing of Australian Scedosporium isolates showing genetic variability and numerous S. aurantiacum

Q37009066

New and emerging treatments for fungal infections

Q37026459

Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans

Q37568516

In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates

Q39730865

Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits

Q39755529

Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group.

Q41582315

In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans

Q41815954

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

Q41842788

Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum

Q44235782

Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery

Q44474678

Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp.

Q44738457

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

Q45051224

Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome

Q45198277

Disseminated Scedosporium prolificans infection and survival of a child with acute lymphoblastic leukemia

Q46428198

Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine

Q48238445

Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis.

Q51187145

Disseminated Scedosporium prolificans (S. inflatum) infection after single-lung transplantation.

Q54200748

Potted plants in hospitals as reservoirs of pathogenic fungi

Q56700957

Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient

Q57746324

P433

issue

P921

main subject

Scedosporium prolificans

Q7430684

emerging pathogen

Q108429945

P304

page(s)

343-350

P577

publication date

2008-12-12

P1433

published in

Medical Mycology

Q6806389

P1476

title

Scedosporium prolificans: an emerging pathogen in France?

P478

volume

Reverse relations

cites work (P2860)

Q46281613	A cluster of scedosporiosis in lung transplant candidates and recipients: The Zurich experience and review of the literature.
Q38284463	Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Q51367219	Disseminated Scedosporium prolificans infection in a German Shepherd dog.
Q33827090	Disseminated Scedosporium/Pseudallescheria infection after double-lung transplantation in patients with cystic fibrosis
Q38738085	Early diagnosis of invasive mould infections and disease
Q34552760	Epidemiology of visceral mycoses in autopsy cases in Japan: the data from 1989 to 2009 in the Annual of Pathological Autopsy Cases in Japan
Q41516902	Infective endocarditis caused by Scedosporium prolificans infection in a patient with acute myeloid leukemia undergoing induction chemotherapy.
Q37454259	Locally extensive angio-invasive Scedosporium prolificans infection following resection for squamous cell lung carcinoma
Q24633163	Melanized Fungi in Human Disease
Q35214490	Susceptibility and diversity in the therapy-refractory genus scedosporium
Q37469829	Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Q37910256	Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment